These results together suggest that, since the MAPK survival pathway was blocked by trametinib, CD133 could suppress apoptosis and promote resistance to trametinib by activating an AKT/phospho-BAD survival pathway in human melanoma cells. This evidence concerns the gene AKT1 and melanoma.